TORONTO, ONTARIO--(Marketwire - Feb. 7, 2013) - Toronto-based Integran Technologies Inc. (Integran) today announced its first issued patent pertaining to the use of its metallurgical nano-technologies for enhancing the durability, reliability and longevity of biomedical implants. US Patent 8,273,117 discloses a "Low Texture Quasi-Isotropic Stent" having superior mechanical properties for use in the treatment of coronary artery disease.
Integran's CEO Gino Palumbo stated: "We are currently developing several biomedical applications for our nano-engineered materials and we are very pleased that the US Patent & Trademark Office has recognized the applicability of our novel grain boundary engineering (GBE®) nano-technology to conventional metallic implant alloys."
About Integran Technologies, Inc.
Integran is a world leader in advanced metallurgical nano-technologies, providing a broad international base of customers with advanced process & product design solutions through R&D, material sales, contract manufacturing and technology licensing. Integran and its predecessor organizations have been at the forefront of metallurgical nano-technology development for over twenty years. Integran has established an international reputation for excellence in materials technology development and commercialization. Integran owns the intellectual property rights for the cost-effective production of metallurgical nano-structures with over 300 patents and patent filings dealing with the structure, composition, processing and application of its revolutionary materials.